Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer

A Randomized, Double-blind, Multicenter Phase III Trial of Adebrelimab (SHR-1316) Plus S-1 and Oxaliplatin (SOX) Versus Placebo Plus S-1 and Oxaliplatin in the Perioperative Treatment of Resectable Gastric or Gastroesophageal Junction Cancer

This study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate the efficacy, safety and tolerability of the two combination regimens.

Study Overview

• Status: Recruiting
• Conditions: Locally Advanced Gastric or Gastroesophageal Junction Cancer
• Intervention / Treatment: Drug: Adebrelimab plus S-1 and oxaliplatin; Drug: Adebrelimab blank preparation plus S-1 and oxaliplatin.

• Study Type: Interventional
• Enrollment (Estimated): 874
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Bin Bai; Phone Number: +0518-81220121; Email: bin.bai@hengrui.com

Study Locations

• China
  • Beijing Municipality
    • Beijing, Beijing Municipality, China, 10000
      • Recruiting
      • Beijing Cancer Hospital
      • Principal Investigator: Lin Shen
      • Principal Investigator: Jiafu Ji

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patients with pathologically confirmed gastric cancer or gastroesophageal junction cancer.
2. Age: ≥18 years old, <75 years old, both male and female are eligible.
3. Before entering the study, the investigator has evaluated and determined that the subject is suitable and plans to undergo neoadjuvant therapy + radical surgery for curative purposes.
4. Gastric cancer or gastroesophageal junction cancer applicable to the 8th edition of the AJCC gastric cancer staging criteria.
5. Fresh specimens (preferred) or formalin-fixed, paraffin-embedded tumor tissue blocks or unstained tumor specimen sections obtained within 6 months before randomization can be provided.
6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1.
7. Expected survival ≥ 6 months.
8. Adequate organ and bone marrow function.
9. Female subjects are either infertile or fertile, with a negative serum pregnancy test result within 3 days before the start of study medication and not in the lactation period. Fertile female subjects and male subjects whose partners are fertile must agree to avoid sperm/egg donation from the time of signing the informed consent form until 6 months after the last administration of the investigational drug, and comply with relevant contraceptive requirements.
10. Consent has been obtained from the individual and the informed consent form has been signed, willing and able to comply with planned visits, study treatment, laboratory tests, and other trial procedures.

Exclusion Criteria:

1. Gastric cancer known to be squamous cell carcinoma, undifferentiated carcinoma or other histological types, or adenocarcinoma mixed with other histological types.
2. Gastric esophageal junction cancer, Siewert type I; or Siewert type II with esophageal invasion length ≥ 4 cm; or other cases not suitable for clinical staging assessment using the 8th edition of the AJCC gastric cancer staging criteria, or not suitable for conventional surgical methods or approaches for gastric cancer.
3. The subject's weight has decreased by more than 20% within 2 months before randomization.
4. Previous anti-tumor treatment for gastric cancer/gastric esophageal junction cancer (including chemotherapy, radiotherapy, immunotherapy, endocrine therapy, targeted therapy, biological therapy or tumor embolization).
5. Known allergy to any component of the investigational drug (including adibelimab/placebo, tegafur, and oxaliplatin), or allergy to humanized monoclonal antibody products.
6. Diagnosis of any other malignant tumor within 5 years before entering the study, except for locally treatable and cured skin basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, ductal carcinoma in situ of the breast, and papillary thyroid carcinoma.
7. History of immunodeficiency (including positive HIV test, other acquired or congenital immunodeficiency diseases) or organ transplantation (including allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation, etc.); history of active autoimmune disease, except for immune disorders that do not require systemic treatment (such as vitiligo, psoriasis, etc.) or autoimmune diseases that can be improved through hormone replacement therapy (such as type 1 diabetes or hypothyroidism).
8. Severe, unhealed or open wounds, active ulcers, or untreated fractures.
9. Active severe digestive system diseases.
10. Presence of interstitial pneumonia or interstitial lung disease.
11. Severe cardiovascular or metabolic diseases.
12. Active HBV or HCV infection (HBsAg positive and viral copy number ≥ 2000 IU/mL, HCV antibody positive and HCV RNA above the upper limit of normal at the research center), or co-infection with hepatitis B and hepatitis C.
13. Active tuberculosis infection within 1 year before randomization (including but not limited to pulmonary tuberculosis, intestinal tuberculosis, etc.), or a history of active tuberculosis infection more than 1 year ago but without regular treatment.
14. Severe infection within 4 weeks before randomization.
15. Known history of abuse of psychotropic drugs or drug addiction.
16. Presence of other serious physical or mental diseases or abnormal laboratory tests that may increase the risk of participation in the study, or interfere with the study results, and patients considered unsuitable for participation in the study by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment group A: Adebrelimab with SOX.	Drug: Adebrelimab plus S-1 and oxaliplatin; Adebrelimab plus S-1 and oxaliplatin
Experimental: Treatment group B: placebo with SOX.	Drug: Adebrelimab blank preparation plus S-1 and oxaliplatin.; Adebrelimab blank preparation plus S-1 and oxaliplatin.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Investigator-assessed EFS	Assessments BY INVESTIGATORS	About 8 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete response (pCR) rate as assessed by the Pathology Review Committee (PRC)	Complete remission (pCR) rates after surgery	About 3 years
Rate of pathologically significant response (MPR) as assessed by the Pathology Review Committee (PRC)	Pathologically significant response (MPR) rate after surgery	About 3 years
EFS as assessed by an independent review committee (IRC)	Independent Review Committee (IRC) evaluation	About 8 years
DFS, as assessed by investigator /IRC	Investigator /IRC assessment	About 8 years
pCR rate by central pathological evaluation	Central pathological evaluation was studied	About 3 years
R0 resection rate of neoadjuvant therapy evaluated by investigators in different treatment groups	Patients who did not undergo surgery for gastric or gastroesophageal junction cancer because of various conditions other than disease progression were evaluated by the investigator	About 8 years
D2 radical resection rate of neoadjuvant therapy evaluated by investigators in different treatment groups	Patients who did not undergo surgery for gastric or gastroesophageal junction cancer because of various conditions other than disease progression were evaluated by the investigator	About 8 years
objective response rate (ORR) of neoadjuvant therapy evaluated by investigators in different treatment groups	Patients who did not undergo surgery for gastric or gastroesophageal junction cancer because of various conditions other than disease progression were evaluated by the investigator	About 8 years
The incidence of adverse events (AE) were evaluated according to NCI-CTCAE 6.0	NCI-CTCAE 6.0 was used for evaluation	About 4 years
The severity of serious adverse events (SAE) were evaluated according to NCI-CTCAE 6.0	NCI-CTCAE 6.0 was used for evaluation	About 4 years

Collaborators and Investigators

• Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd

Study record dates

Study Major Dates

• Study Start (Actual): May 7, 2026
• Primary Completion (Estimated): December 1, 2029
• Study Completion (Estimated): February 1, 2034

Study Registration Dates

• First Submitted: April 3, 2026
• First Submitted That Met QC Criteria: April 3, 2026
• First Posted (Actual): April 13, 2026

Study Record Updates

• Last Update Posted (Actual): May 13, 2026
• Last Update Submitted That Met QC Criteria: May 12, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Organic Chemicals; Coordination Complexes; Oxaliplatin; S 1 (combination)
• Other Study ID Numbers: SHR-1316-309

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No